Stocks and Investing Stocks and Investing
Thu, January 25, 2018
Wed, January 24, 2018

Cory Kasimov Maintained (BMRN) at Buy with Decreased Target to $129 on, Jan 24th, 2018


Published on 2024-10-26 02:07:21 - WOPRAI, Cory Kasimov
  Print publication without navigation


Cory Kasimov of JP Morgan, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $131 to $129 on, Jan 24th, 2018.

Cory has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 0 agree with Cory's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Cory


  • Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017
  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $119 on, Friday, October 27th, 2017
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $105 on, Friday, October 27th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $124 on, Thursday, October 19th, 2017
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $142 on, Thursday, October 19th, 2017
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017

Contributing Sources